Brought to you by 
MGI Pharma acquires Hexalen from MedImmune
04 Jan 2022
Executive Summary
MGI Pharma (cancer and rheumatology disorders) has acquired MedImmune's (infectious diseases, immune regulation, and cancer) Hexalen (altretamine) for $7.2mm (payable in quarterly installments of $1.2mm each over six quarters) plus sales royalties for 10 years. The drug is an orally administered chemotherapeutic compound to treat ovarian cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MGI Pharma acquires Hexalen from MedImmune
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice